Skip to main content

Table 6 Blood cell counts

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Ex vivo pravastatin pretreatment experiment recipients
Blood samples Healthy + DMEM BMC recipients ( n = 5) Healthy + pravastatin BMC recipients ( n = 5) CKD + DMEM BMC recipients ( n = 10) CKD + pravastatin BMC recipients ( n = 9)
White blood cells 5.86 ± 1.20 5.52 ± 0.93 4.63 ± 1.05 5.42 ± 1.18
Lymphocytes 3.30 ± 1.35 2.54 ± 0.29 2.60 ± 0.86 2.94 ± 0.51
Midpopulation 1.58 ± 0.29 1.56 ± 0.31 1.18 ± 0.28 1.59 ± 0.45
Granulocytes 0.98 ± 0.45 1.38 ± 0.53 0.84 ± 0.35 1.08 ± 0.52
Red blood cells 6.66 ± 0.40 6.59 ± 0.36 6.24 ± 0.59 6.63 ± 0.23
Hemoglobin 8.06 ± 0.47 7.90 ± 0.42 7.63 ± 0.72 7.86 ± 0.29
Hematocrit 0.33 ± 0.05 0.33 ± 0.019 0.31 ± 0.029 0.33 ± 0.010
Mcv 49.08 ± 0.83 50.08 ± 1.08 50.10 ± 2.09 49.35 ± 0.78
Mchc 24.38 ± 0.22 23.94 ± 0.38 24.18 ± 0.43 24.08 ± 0.36
Rdw 15.44 ± 0.43 15.22 ± 0.29 15.63 ± 1.125 15.151 ± 0.818
Platelets 736 ± 68 697 ± 49 634 ± 99 699 ± 55
Systemic in vivo pravastatin treatment
Blood samples CKD (n = 6) CKD + pravastatin ( n = 5)   
White blood cells 4.81 ± 0.89 4.50 ± 1.16   
Lymphocytes 2.87 ± 0.59 2.90 ± 0.97   
Midpopulation 1.27 ± 0.39 0.90 ± 0.19   
Granulocytes 0.65 ± 0.16 0.68 ± 0.13   
Red blood cells 6.38 ± 0.22 6.25 ± 0.15   
Hemoglobin 7.58 ± 0.32 7.52 ± 0.18   
Hematocrit 0.32 ± 0.01 0.31 ± 0.01   
Mcv 49.37 ± 0.79 49.96 ± 0.32   
Mchc 24.05 ± 0.25 24.14 ± 0.23   
Rdw 15.13 ± 0.63 15.14 ± 0.68   
Platelets 681 ± 42 666 ± 41   
  1. Data presented as mean ± standard deviation. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium. Mcv, Mean Corpuscular Volume; Mchc, Mean Corpuscular Hemoglobin Concentration; Rdw, Relative Distribution Width.